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H I G H L I G H T S
 Urinary excretion of three speciﬁc, secondary, oxidized metabolites (oxo-MPHP, OH-MPHP and cx-MPHxP) of DPHP was monitored following oral uptake
by ﬁve volunteers.
 Urinary elimination half-lives for these metabolites are between 6 and 8 h.
 22.9% of the DPHP dose is excreted as one of the above three metabolites within 24 h, until 48 h post dose an additional 1–2% is excreted.
 Based upon molar excretion fractions the DPHP intake of the general public and of workers can be calculated from urinary metabolite levels.
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A B S T R A C T
Di(2-propylheptyl) phthalate (DPHP), a high molecular weight phthalate, is primarily used as a plasticizer
in polyvinyl chloride and vinyl chloride copolymers for technical applications, as a substitute for other
phthalates currently being scrutinized because of endocrine disrupting effects.
We determined urinary excretion fractions of three speciﬁc DPHP metabolites (mono-2-(propyl-6-
hydroxy-heptyl)-phthalate (OH-MPHP), mono-2-(propyl-6-oxoheptyl)-phthalate (oxo-MPHP) and
mono-2-(propyl-6-carboxy-hexyl)-phthalate (cx-MPHxP)) after oral dosing of ﬁve volunteers with
50 mg labelled DPHP-d4 and subsequent urine sampling for 48 h. These excretion fractions are used to
back calculate external intakes from metabolite measurements in spot urine analysis. Following
enzymatic hydrolysis to cleave possible conjugates, we determined these urinary metabolites by HPLC–
NESI–MS/MS with limits of quantiﬁcation (LOQ) between 0.3 and 0.5 mg/l.
Maximum urinary concentrations were reached within 3–4 h post dose for all three metabolites;
elimination half-lives were between 6 and 8 h. We identiﬁed oxo-MPHP as the major oxidized metabolite
in urine representing 13.5  4.0% of the DPHP dose as the mean of the ﬁve volunteers within 48 h post
dose. 10.7  3.6% of the dose was excreted as OH-DPHP and only 0.48  0.13% as cx-MPHxP. Thus, within
48 h, 24.7  7.6% of the DPHP dose was excreted as these three speciﬁc oxidized DPHP metabolites, with
the bulk excreted within 24 h post dose (22.9  7.3%).
These secondary, oxidized metabolites are suitable and speciﬁc biomarkers to determine DPHP exposure.
In population studies, however, chromatographic separation of these metabolites from other isomeric di-
isodecyl phthalate (DIDP) metabolites is warranted (preferably by GC–MS) in order to distinguish DPHP
from general DIDP exposure. Palatinol1, Hexamoll1 and DINCH1 are registered trademarks of BASF SE,
Germany.
ã 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Di(2-propylheptyl) phthalate (DPHP), CAS No. 53,306-54-0, a
REACH (Regulation (EC) No. 1907/2006) registered high molecular
weight phthalate, is primarily used as a plasticizer in polyvinyl-
chloride and vinyl chloride copolymers for technical applications.
DPHP, which is marketed under, e.g., the trade name “Palatinol1
10-P”, is produced by esteriﬁcation of phthalic anhydride with a
C10 alcohol consisting of 90% 2-propyl-heptanol and 10% 2-propyl-
4-methylhexanol or 2-propyl-5-methylhexanol. There are current-
ly two different C10 phthalates on the market. DPHP and di-
isodecyl phthalate (DIDP) as described with the CAS No. 68,515-49-
1: 1,2-benzenedicarboxylic acid, di-C9-11-branched alkyl esters,
C10-rich. Another DIDP described by CAS No. 26,761-40-0 is no
longer produced in Europe and is not REACH registered. Further-
more, there are two C9 phthalates (di-isononyl phthalates, DINPs)
on the market: DINP1 (1,2-benzenedicarboxylic acid, di-C8-10-
branched alkyl esters, C9-rich, described with CAS No. 68,515-48-0
and DINP2 (di-isononyl phthalate) with CAS No. 28,553-12-0.
While DINP2 solely consists of C9 isomers DINP1 contains up to
10% C10 isomers. Thus, the broad isomer distribution of DINP1
(including C10 moieties) can also interfere with the analytical
detection of both DIDP and DPHP. The lack of sufﬁcient analytical
separation of DINP and DIDP resulted in a group-TDI by EFSA (EFSA,
2005) for food contact applications (Commission Regulation (EU)
No. 10/2011).
The phthalates DINP, DPHP and DIDP are currently used as
substitutes for di-(2-ethylhexyl) phthalate (DEHP) which is listed
under REACH as a substance of very high concern (SVHC). Based on
their low volatility and low vapor pressure, the C10 phthalates
DPHP and DIDP are predominantly used in high temperature-
resistant products such as electrical cables, carpet backing and car
interiors, but they are also used for outdoor applications like
rooﬁng membranes or tarpaulins (European Commission, 2003;
NICNAS, 2003, 2008; Wittassek, 2008). DPHP is currently not used
in food contact. Because plasticizers are not chemically bound in
PVC products and thus can migrate out of these products, exposure
of humans and the environment is possible. Therefore, aFig. 1. Proposed human metabolism of DPHP, based upon its major 2-propylheptyl alky
chains; the remainder is made up of 2-propyl-4-methylhexyl and 2-propyl-5-methylhecollaborative project between the German Federal Ministry for
the Environment, Nature Conservation, Building and Nuclear
Safety (BMUB) and the German Chemical Industry Association
(VCI) evaluated a speciﬁc human biomonitoring method to
determine exposure of the general population to DPHP using
reliable and speciﬁc urinary biomarkers (Federal Ministry for the
Environment, 2010). We recently developed such a method for
DINCH1 (di-isononyl-cyclohexane-1,2-dicarboxylate), a non-aro-
matic high molecular weight phthalate substitute mainly intended
for sensitive applications such as toys, food contact materials and
medical devices (Koch et al., 2013a,b; Schütze et al., 2012, 2014).
For DPHP, however, exposure needs to be distinguishable from
DIDP/DINP exposure. Previous exposure assessments based on
human biomonitoring have reported the cumulative exposure
(Kasper-Sonnenberg et al., 2012; Koch et al., 2009) to all phthalates
containing C10 alkyl chains (DPHP, DINP, DIDP), because the
complex isomeric composition of DINP/DIDP interfered with the
selective detection of the DPHP speciﬁc 2-propyl-heptyl based side
chain metabolites.
We used the method developed by Gries et al. (2012) to reliably
detect and quantify DHPH metabolites in the presence of other
DIDP/DINP metabolites. Wittassek and Angerer, 2008 showed that
DPHP is metabolized similarly to DEHP (Koch et al., 2004), i.e., the
monoester is formed by ester cleavage in a ﬁrst step followed by
extensive v and v-1 oxidation of the remaining single alkyl side
chain. A metabolism scheme of DPHP is presented in Fig. 1. The
secondary, oxidized metabolites are the predominant metabolites.
The monoester MPHP is only a minor metabolite (<1% formed from
the parent compound and excreted with urine), which is typical for
all high molecular weight phthalates. The secondary metabolites
have an added analytical beneﬁt in that they are not subject to
issues of sample contamination as described by Kato et al. (2004)
and Schindler et al. (2014).
We investigated renal excretion and metabolic conversion of
DPHP by measuring three oxidized metabolites of the propylheptyl
side-chain, mono(propyl-6-oxo-heptyl) phthalate (oxo-MPHP),
mono(propyl-6-hydroxyheptyl) phthalate (OH-MPHP) and mono
(propyl-6-carboxyhexyl)- phthalate (cx-MPHxP) following orall-chain isomer. The 2-propyl-heptyl side chain makes up about 90% the DPHP side
xyl side chains. The stars (*) depict the positions of the deuterium label.
Table 1
LC–MS/MS retention times, mass transitions and dwell times for the labeled and
non-labeled DPHP metabolites.
Metabolite Rt Parent Daughter Dwell time
(min) (m/z) (S)
cx-MPHxP 19.83 335.16 187.04 0.1
cx-MPHxP-d4 19.81 339.12 187.04 0.1
OH-MPHP 20.15 321.13 121.02 0.1
OH-MPHP-d4 20.13 325.16 125.04 0.1
oxo-MPHP 19.65 319.12 121.02 0.1
oxo-MPHP-d4 19.60 323.15 124.98 0.1
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volunteers. The fraction of excreted metabolite is used to
determine conversion factors which enable the back calculation
of the (daily) intake of DPHP (external dose) as described by Kohn
et al. (2000) and David (2000).
2. Materials and methods
2.1. Experimental design
Di(2-propylheptyl) phthalate (DPHP) was orally dosed as ring-
deuterated DPHP-d4 to ﬁve healthy male volunteers, aged between
27 and 49 years, with body weights between 77 and 94 kg. The
volunteers did not have any known occupational exposure to DPHP
or to other plasticizers. Fifty milligram of DPHP-d4 was dissolved in
0.25 ml of ethanol and mixed in an edible wafﬂe cup with a
chocolate surface containing coffee or tea during breakfast. This
resulted in doses for the ﬁve individuals of between 0.54 and
0.66 mg/kg body weight. The DPHP dose was considerably below
the lowest NOAEL (no observed adverse effect level) for DPHP (BfR
Opinion No., 2011; Bhat et al., 2014) and comparable to the DINP
(Koch and Angerer, 2007) or DINCH1 dose levels (Schütze et al.,
2014) of previous human metabolism studies. The DPHP dose was
several orders of magnitude above exposure levels expected for the
general population. Stable-isotope labeled DPHP-d4 was used to
exclude possible background exposures. Volunteers were dosed at
the Institute for Prevention and Occupational Medicine of the
German Social Accident Insurance, Institute of the Ruhr-Universi-
tät Bochum (IPA), frozen samples of urine were shipped to
Currenta for quantiﬁcation of the metabolites. The ﬁrst urine
samples were collected prior to dosage at 10:00 a.m. followed by
subsequent urine samples collected over 48 h post-dosing. The
volunteers recorded the time of the void of each sample. The urine
volume of each individual sample was determined as the
difference between the weight of the ﬁlled and the empty
container. In all, we obtained 122 urine samples, i.e., between
20 and 29 samples from each volunteer. The total 48 h urine
volume ranged from 4133 to 8298 ml, depending on the volunteer.
All urinary samples were frozen at 18 C immediately after
delivery. The study was carried out in accordance with the code of
ethics of the World Medical Association (Declaration of Helsinki)
and was approved by the ethical review board of the Medical
Faculty of the Ruhr-University Bochum (Reg. No.: 4022-11). The
study design was presented to the volunteers in written form, and
all participants provided written informed consent.
2.2. Chemicals
Acetonitrile (supra solv), methanol (supra solv), glacial acetic
acid (p.a.) and hydrochloric acid 37% (p.a.) were purchased from
Merck, Darmstadt, Germany. Ammonium acetate (p.a.) was
purchased from Fluka, Taufkirchen, Germany. Formic acid (99%,
ULC/MS) was purchased from Biosolve B.V., Valkenswaard, The
Netherlands. Water from a millipore water cleaning system was
used and b-glucuronidase from Escherichia coli K12 was pur-
chased from Roche, Mannheim, Germany. DPHP-d4 was provided
by BASF SE. The following standards were synthesized at the
Institut für Dünnschichttechnologie e.V. (IDM), Teltow, Germany:
mono-2-(propyl-6-hydroxy-heptyl)-phthalate (OH-MPHP), mono-
2-(propyl-6-oxo-heptyl)-phthalate (oxo-MPHP), mono-2-(propyl-
6-carboxy-hexyl)- phthalate (cx-MPHxP), mono-2-(propyl-6-hy-
droxy-heptyl)-phthalate-d4 ring deuterated (OH-MPHP-d4),
mono-2-(propyl-6-oxo-heptyl)-phthalate-d4 ring deuterated
(oxo-MPHP-d4), and mono-2-(propyl-6-carboxy-hexyl)-phthal-
ate-d4 ring deuterated (cx-MPHxP-d4). The purity of all com-
pounds was determined by 1H-NMR and was 95%.2.3. Standards
The study design is based on dosing of ring labeled DPHP-d4;
therefore, the target substances were the respective d4-ring
labeled metabolites. Ten milligram of each metabolite (OH-MPHP-
d4, oxo-MPHP-d4 or cx-MPHxP-d4) were weighed separately into
a 10 ml glass volumetric ﬂask and diluted to volume with
acetonitrile (1000 mg/l). From these stock solutions, a multi-
component starting solution was prepared by diluting 100 ml of
each in a 10 ml glass volumetric ﬂask ﬁlled with acetonitrile. This
starting solution (10 mg/l) was further diluted for the preparation
of the working standards to achieve ﬁnal standard concentrations
of 1 mg/l, 0.1 mg/l, 0.01 mg/l and 0.001 mg/l.
For the purpose of internal standardization, we used the non-
labeled DPHP metabolite standards. Internal standard stock
solutions were prepared by dilution of 10 mg of OH-MPHP, oxo-
MPHP or cx-MPHxP in 10 ml volumetric ﬂasks with acetonitrile
(1000 mg/l). Starting solution A was prepared by diluting 100 ml of
each of the three stock solutions into a 10 ml volumetric ﬂask
(10 mg/l) to the mark with acetonitrile. For the preparation of
solution B 1 ml of solution A was diluted in a 10 ml volumetric ﬂask
to its nominal volume with acetonitrile (1 mg/l).
2.4. Sample preparation
Urine samples (or standards) were thawed and equilibrated to
room temperature. For enzymatic hydrolysis, 10 ml of b-glucuron-
idase and 20 ml of the internal standard solution in 200 ml 1 M
ammonium acetate buffer (pH 6.5) were added to 1000 ml of each
sample and mixed. Samples were incubated at 37 C overnight.
Thereafter, all samples were acidiﬁed to pH 2 with hydrochloric
acid (37%) and extracted with tert-butylmethylether, mixed with a
vortex mixer for 10 min and centrifuged at 2200 g for 10 min at
10 C. The upper phase was aspirated with a Pasteur pipette and
placed into a glass test tube, and the samples were dried at 35 C
with nitrogen. All samples were re-dissolved in 200 ml of methanol
for HPLC–MS/MS analysis. The creatinine concentration in each
urine sample was measured according to the Jaffé method
(Taussky, 1954).
2.5. High performance liquid chromatography–tandem mass
spectrometry
Chromatographic separation was performed on a Waters
Alliance HPLC System equipped with a Zorbax Eclipse Plus C18
column (2.1 mm  150 mm  3.5 mm (Agilent)) at 30 C. A tertiary
system (A: methanol, B: water and C: formic acid) was used to
separate the metabolites with the following conditions: at start,
10 ml was injected onto the column with 10% A, 80% B and 10% C,
ﬂow was 0.2 ml/min and constant during the whole analysis which
lasted 25 min. Metabolites were separated by an increasing
methanol gradient, i.e., methanol (A) was increased from 10% to
90% within 15 min while water (B) was reduced to 0%. Solvents A
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Fig. 2. Chromatograms of a representative pre-dose (A) and post-dose (B) urine sampl
dotted line represents the non-labeled internal standards, the bold line the D4-labeled
Table 2
Within-day and between-day precision data.
Analyte Within-day precision (n = 8) Between-day precision (n = 5)
Conc. Recov. R.S.D. Conc. Recov. R.S.D.
(mg/l) (%) (%) (mg/l) (%) (%)
cx-MPHxP-d4 1 109 4.6 – – –
10 108 3.2 10 111 3.9
100 108 1.5 100 106 10.2
OH-MPHP-d4 1 108 2.2 – – –
10 101 3.8 10 102 1.1
100 103 2.4 100 103 1.7
oxo-MPHP-d4 1 100 6.5 – – –
10 97 2.8 10 99 4.9
100 101 5.3 100 99 2.9
G. Leng et al. / Toxicology Letters 231 (2014) 282–288 285(90%) and B (0%) were kept constant for 2 min and then a gradient
was used to reach 10% A and 80% B at 18 min. These conditions
were kept for 7 min until 25 min when the analysis was ﬁnished. C
was kept constant at 10% during the analysis. The mass
spectrometric detection and quantiﬁcation was performed on a
Waters Quattro Ultima MS/MS with negative electrospray ioniza-
tion (NESI) in MRM mode. Mass transitions are depicted in Table 1.
Further details are given in Gries et al. (2012).
2.5.1. Calibration and quantiﬁcation
Calibration was carried out by spiking 1 ml of water with
concentrations ranging from 0.1 mg/l to 5000 mg/l of each
deuterated standard. All calibration samples were analyzed as
described in the sample section. Due to the high dynamic range of
the HPLC–MS/MS a calibration range up to 5000 mg/l of each
metabolite can be obtained in case a quadratic curve ﬁt is used
(coefﬁcient of correlation better than 0.99 for each analyte). The
wide calibration range was desirable for the determination of someB: post- dose sample
100
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e with extracted ion chromatograms for the three oxidized DPHP metabolites. The
 metabolites generated by the oral dose of D4-labeled DPHP.
Fig. 3. Elimination of the three oxidized DPHP metabolites in urine over time (48 h)
for the ﬁve volunteers is shown in Fig. 3A (in mg/L), B (in mg/g creatinine) and C
(absolute amount in mg), calculated for 6 h increments. The bold boxes represent
mean values calculated over all ﬁve volunteers; the bars depict the ranges among
the ﬁve volunteers.
286 G. Leng et al. / Toxicology Letters 231 (2014) 282–288high metabolite concentrations expected in this dosing study.
Samples with concentrations above the calibration range were
analyzed again after sample dilution with water. The calibration
curves were obtained by plotting the quotient of the peak areas of
the target deuterated analytes and the corresponding unlabeled
internal standards against the standard concentrations.
2.5.2. Quality control and validation
As quality control samples were not available, they had to be
prepared in the laboratory with spiked urine samples to cover
different concentration ranges (1 mg/l, 10 mg/l or 100 mg/l of each
labeled metabolite). One millilitre aliquots of these control
samples were stored frozen at 18 C. Two samples with either
10 or 100 mg/l concentration of each deuterated standard were
analyzed during the analysis sequences for each volunteer on ﬁve
different days to determine between day precision data. The
within-day precision was obtained by analyzing pooled urine
samples in three concentrations of each deuterated standard as
described above. These samples were analyzed eight times in a row
and all samples were quantiﬁed against the calculated calibration
curve. Moreover, the background of unlabeled DIDP/DPHP
metabolites in the samples was tested in several experiments.
As there was no signiﬁcant interfering DIDP/DPHP background
observed in the dosing samples (DIDP/DPHP metabolite levels
were consistent below 2 mg/l), the samples were spiked with
200 mg/l of each unlabeled DPHP metabolite as internal standards.
Quality control data (relative recovery, precision), depicted in
Table 2, was acceptable and comparable to that of Gries et al.
(2012).
2.5.3. Limit of detection (LOD) and limit of quantiﬁcation (LOQ)
Detection limits were calculated according to the calibration
curve method (DIN 32645) by use of the six lowest calibration
points. LODs were 0.1 mg/l for cx-MPHxP-d4 and 0.2 mg/l for OH-
MPHP-d4 and oxo-MPHP-d4. The corresponding LOQs were 0.3 mg/
l, 0.5 mg/l and 0.5 mg/l for cx-MPHxP-d4, OH-MPHP-d4 and oxo-
MPHP-d4, respectively.
2.6. Statistical analysis
Statistical analysis was carried out using Microsoft Excel 2010.
Exponential regression modeling was used to calculate exponen-
tial functions for decreasing metabolite levels after cmax. C(t) is the
time dependent concentration, whereas C0 is the maximum
concentration. K is the metabolite speciﬁc renal excretion constant.
Dt represents the time beginning from cmax till the end of sample
collection.
CðtÞ ¼ C0  expðkDtÞ
Furthermore, metabolic half-time is given by the natural
logarithm of two over k (according to Clark and Smith, 1986).
3. Results
The LOQs of the HPLC–MS/MS method applied were sufﬁciently
low to quantify the d4-ring-labelled DPHP metabolites in all post-
dose urine samples obtained from this dosing study. LC–MS/MS
chromatograms in Fig. 2A and B illustrate the appearance of the d4-
ring-labeled oxidized DPHP metabolites in the post-dose urine
samples. In the pre-dose urine samples, no d4-ring-labelled DPHP
metabolites could be detected. As explained above, we used non-
labeled propylheptyl derived DPHP metabolite standards for
internal standardization. In some urine samples, a background
trace level of isomeric, oxidized (non-labelled) DIDP metabolites
was visible, but at levels much lower than the spiked DPHP
standards (maximum concentrations of 2 mg/l, not shown). Thus,with spiked internal standard concentrations at 200 mg/l, the
omnipresent but low background exposure to DIDP/DPHP did not
interfere with the study design. Elimination kinetics could be
monitored and speciﬁc metabolic conversion factors could be
established. In the chromatograms of Fig. 2B, additional peaks with
same fragmentation patterns as the propylheptyl derived oxidized
standards emerged, albeit at different retention times. These peaks
most likely originate from the minor alkyl chain isomers of DPHP
(2-propyl-4-methylhexyl or 2-propyl-5-methylhexyl side chain)
and/or from oxidative modiﬁcations other than in the v- or v-1-
position. All further quantitative data are based on the sole
integration of the speciﬁc propylheptyl derived oxidized isomer
peaks present as analytical standard substances.
The elimination of these speciﬁc DPHP metabolites in urine
over time (48 h) for the ﬁve volunteers is shown in Fig. 3A (in mg/l),
B (in mg/g creatinine) and C (absolute amount in mg), calculated for
6 h increments. All forms of presentation clearly depict the rapid
appearance of all three DPHP metabolites in urine after oral dosage.
Table 4
Molar urinary excretion fractions in % of oral dose (mean  standard deviation) for
ﬁve volunteers).
Time cx-MPHxP-d4 OH-MPHP-d4 oxo-MPHP-d4
P
of 3 metab.
(h) (%)
0–24 0.42  0.11 9.91  3.45 12.61  3.90 22.94  7.33
0–48 0.48  0.13 10.70  3.61 13.52  4.04 24.70  7.64
Table 3
Elimination half-lives and times of maximum urinary excretion for the three
oxidized DPHP metabolites after oral dosage (calculated from the ﬁve volunteers).
Parameter Mean tmax SD Mean t1/2 SD
(h)
oxo-MPHP-d4 3.65  1.31 6.51  1.64
OH-MPHP-d4 3.65  1.31 6.87  1.63
cx-MPHxP-d4 4.05  1.39 8.16  0.67
SD: standard deviation.
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metabolites over cx-MPHxP which is excreted at considerably
lower concentrations. All metabolites are excreted rather rapidly
and steadily over the 48 h investigated. However, at 48 h post-dose,
all three metabolites were still detectable. Based upon the
creatinine corrected elimination curve (Fig. 3B), all three
metabolites seem to follow a one-phasic elimination pattern.
Times of maximum urinary excretion for the three oxidized
DPHP metabolites and elimination half-lives calculated from the
individual data of each of the ﬁve volunteers are depicted in
Table 3.
Molar excretion fractions in percent of the oral dose were
calculated by using the respective molecular weights of the
metabolites cx-MPHxP-d4 (340.39 g/mol), OH-MPHP-d4 (326.40 g/
mol), and oxo-MPHP-d4 (324.39 g/mol). Total excreted amount
was estimated as the sum of all samples taken per volunteer and
taking into account all three metabolites (see Table 4). Oxo-MPHP
is the most abundant metabolite, representing in the mean over
the ﬁve volunteers 13.5% of the oral DPHP dose in urine after 48 h,
closely followed by OH-MPHP (10.7%). Cx-MPHxP (0.5%) is
regarded as a minor metabolite. All three oxidized metabolites
represent about 25% of the dose excreted in urine within 48 h.
4. Discussion
Wittassek and Angerer (2008) reported the ﬁrst results on
human DPHP metabolism, when the senior author ingested a
single DPHP dose of 98 mg during breakfast. In their pilot study
they reported that after 61 h around 34% of the applied dose was
excreted with urine as oxidized metabolites (including approx. 1%
as the simple monoester). Taking into account that they included
other metabolites with oxidative modiﬁcations and that their
sampling time was longer, their data are consistent with the data of
the study reported here.
The data obtained for DPHP in this study is also consistent with
human metabolism data for other high molecular weight
phthalates like DEHP and DINP (Koch et al., 2005, 2007; Anderson
et al., 2011; Kessler et al., 2012). Similar elimination half-lives were
also calculated for all DPHP metabolites (6.51–8.16 h) compared
with DEHP and DINP. They are in good accordance to the respective
metabolite half-lives of DINP (4–8 h; Anderson et al., 2011) and
DEHP (4.6–6.6 h; Kessler et al., 2012).
For DEHP, the three main, oxidized metabolites excreted in
urine represent about 38.6–57.8% of the oral dose, depending onthe study; for DINP, the three main oxidized metabolites excreted
in urine represent about 29.8–37.5% of the dose, depending on the
study. In all these studies, it was shown that an increasing alkyl
chain length of the plasticizer results in a decreased formation of
the simple monoester. Thus, for high molecular weight plasticizers,
the simple monoester is not a relevant urinary metabolite.
Furthermore, since the simple monoester is prone to external
contamination, the oxidized metabolites have to be regarded as the
most suitable biomarkers for monitoring exposure to high
molecular weight phthalates in urine (Koch and Calafat, 2009).
The metabolic conversion factors established in this study for
DPHP based on the ﬁve male volunteers allow a reliable back
calculation from urinary DPHP metabolite levels to external
exposure, and thus enable a solid risk assessment of the human
body burden for the general public as well as for individuals
occupationally exposed. A reliable back-calculation to DPHP
exposure, however, can only be performed, if the above secondary,
oxidized DPHP metabolites are chromatographically separated
from the oxidized metabolites of DIDP/DINP that are generally
present in urine samples of the general population, due to the
omnipresent DIDP/DINP exposures. Gries et al. (2012) have
recently published a GC–HRMS methodology that can unambigu-
ously and reliably quantify these oxidized DPHP metabolites, even
in the presence of high DIDP/DINP body burdens. For 40 random
spot urine samples, they reported a maximum urinary concentra-
tion of 0.93 mg/l oxo-MPHP. Most of the currently available human
biomonitoring data (summarized e.g., in Wittassek et al., 2007,
2011; Koch and Calafat, 2009; Kasper-Sonnenberg et al., 2012) do
not distinguish between oxidized C10 metabolites of DIDP/DINP
and DPHP due to the limited chromatographic resolution of the
HPLC–MS methodology applied. The C10-metabolite levels from
these studies, however, indicate a cumulative C10-phthalate
exposure (DINP/DIDP and DPHP) that is considerably higher than
that for DPHP alone. Future studies using differential integration of
speciﬁc DPHP metabolites next to the cumulative measurement of
C10-phthalate metabolites have to conﬁrm this ﬁnding.
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